Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zymeworks Inc. - Common Stock (NQ:ZYME)

17.94 +1.02 (+6.03%)
Streaming Delayed Price Updated: 9:59 AM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 156,601
Open 17.30
Bid (Size) 17.91 (4)
Ask (Size) 17.96 (6)
Prev. Close 16.92
Today's Range 17.27 - 18.35
52wk Range 9.030 - 17.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
Via Benzinga

Performance

YTD
+21.4%
+21.4%
1 Month
+17.8%
+17.8%
3 Month
+31.3%
+31.3%
6 Month
+90.0%
+90.0%
1 Year
+40.9%
+40.9%

More News

Read More
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
Via Stocktwits
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
From Zymeworks Inc.
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Friday?
Via Chartmill
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
Via Stocktwits
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
Via Stocktwits
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks Announces Participation in Upcoming Investor Conferences
From Zymeworks Inc.
Via GlobeNewswire
Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
From Zymeworks Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Zymeworks Inc. - Common Stock publicly traded?
Yes, Zymeworks Inc. - Common Stock is publicly traded.
What exchange does Zymeworks Inc. - Common Stock trade on?
Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zymeworks Inc. - Common Stock?
The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
What is the current price of Zymeworks Inc. - Common Stock?
The current price of Zymeworks Inc. - Common Stock is 17.94
When was Zymeworks Inc. - Common Stock last traded?
The last trade of Zymeworks Inc. - Common Stock was at 10/10/25 09:59 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS